MAMustapha Kobina Abeka

Mustapha Kobina Abeka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mustapha Kobina Abeka has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Determination of 5‐Hydroxymethylfurfural Content in Marketed Honey: A Modified RP‐HPLC Method

    by Barbara Adu-Brimpong, Abena Amponsaa Brobbey, Joseph Kwasi Adu, John Nii Addotey, Mustapha Kobina Abeka, Isaac Yaw Attah

    Honey is a nutritive sugar alternative, well‐accepted over decades due to its natural source, and a global populace drive toward natural and healthier lifestyle options. Its quality assessment includes 5‐hydroxymethylfurfural (5‐HMF) content, which measures freshness, but has been linked to cancer. The ability to test for this neo‐formed contaminant, 5‐HMF, should therefore not be compromised, even in a resource‐constrained setting. In this study, a modified reversed‐phase HPLC method for the assay of 5‐HMF levels in honey has been developed. A nonpolar C‐18 column of dimension 3.0 × 150 mm; 2.7 μm was the stationary phase of choice, while a combination of 10:90% v/v of methanol and distilled water, with 1% formic acid, was employed as the mobile phase. Detection was by diode array at a wavelength of 295 nm, using an injection volume of 1 μL. At a flow rate of 0.5 mL/min, the total runtime of the method was 8 min, with the average retention time for 5‐HMF recorded at 3.87 ± 0.05 min. Validation of the method was conducted using International Council for Harmonisation guidelines, over the range of 1.25–30.0 μg/mL. It was further employed to quantify 5‐HMF in 20 honey samples on the Ghanaian market with varying origin, extraction source and production state, using methanol as the dissolution solvent to ensure stability of the target compound throughout the analysis. 5‐HMF levels assayed in the honey samples ranged from 0.8176 ± 0.182 to 81.1619 ± 2.1169 mg/kg of honey. At the time of analysis, 5‐HMF contents of all samples except one were within the acceptable limit of ≤ 80 mg/kg of honey, set by the International Honey Commission. The 5‐HMF levels quantified in market samples approved by Ghana’s Food and Drugs Authority were within the acceptable limit. The developed method is comparatively cheaper and can be successfully used to analyse 5‐HMF in honey samples.

  • Open Access

    In Vitro and In Vivo Effect of Xylopic Acid on Cytochrome P450 Enzymes

    by Mary A. Agbenyeku, Regina Appiah-Opong, Ernest Obese, Robert P. Biney, Emmanuel A. Adakudugu, Arnold D. Forkuo, Silas A. Osei, Mustapha K. Abeka, Elvis O. Ameyaw

    Introduction. Xylopic acid (XA), the major constituent of the fruit of Xylopia aethiopica, has shown several pharmacological properties. Traditionally, the plant is used to treat several diseases and is being used in the preparation of several local foods despite the lack of information about its safety, food-drug interaction, and other pharmacokinetic properties. This study, therefore, investigated the effect of XA on rat liver cytochrome P450 (CYP) enzymes in vivo and in vitro. Methods. Inhibition or induction of some isoforms of CYP450 enzymes: CYP 1A1/1A2, 1A2, 2B1/2B2, 3A4, 2D6, and 2C9 were investigated using microsomal fractions of the liver obtained from rats pretreated with a low dose of xylopic acid (LDT) 30mg/kg, high dose of xylopic acid (HDT) 100mg/kg, phenobarbitone (PC) 80mg/kg, and ketoconazole (NC) 100mg/kg, and a no-treatment group received distilled water, with (n=5) animals in each group. The in vitro inhibition of CYP 3A4 was assessed by treating rat liver microsomes with XA. Results. Xylopic acid induced CYP 1A1/1A2, 1A2, 2D6, and 2C9, inhibited CYP 3A4, and had no effect on 2B1/2B2. Conclusion. The findings would help mitigate toxicity and therapeutic failure especially in cases of coadministration of medications with food containing XA, with metabolism altered by the latter.